3月3日 - ** 制药商万达制药VNDA.O股价盘前上涨2.2%至8.35美元
** 公司称美国食品药品管理局将举行罕见的公开听证会，审查其扩大睡眠药物Hetlioz治疗时差紊乱的申请
** 当长途旅行扰乱了人体的内部时钟，导致疲劳和睡眠不佳时，就会出现时差现象。
** VNDA 表示，这是 40 多年来首次举行此类药物审批听证会，而且是在 FDA 最初拒绝该申请后提出上诉之后举行的。
** Hetlioz 已被批准用于治疗两种罕见的睡眠障碍
** 2025 年 VNDA 股价上涨约 84%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.